lonely-shutterstock-com
Lonely / Shutterstock.com
4 February 2016Big PharmaSam Bailey

Uncertainties in the SPC field

Supplementary protection certificates (SPCs) offer valuable extensions to the protection offered by the patent system for new pharmaceuticals and plant protection products in Europe. They have the potential to provide up to five years of additional protection for the product on the expiry of the basic patent to compensate the innovator for the delay in commercial exploitation due to extended authorisation procedures required to bring these products to market.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
16 March 2026   Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.
Big Pharma
10 March 2026   UK government funding will support the London-based IP crime unit until 2029, as EUIPO and European authorities step up efforts to tackle unsafe counterfeits.
Big Pharma
11 February 2026   Courts on both sides of the Atlantic recorded a flurry of settlements this week, as Astellas, GSK, and Alexion drew a line under long-running disputes with generic rivals.